Fecal Microbiota Transplantation

Abstract

Fecal microbiota transplantation (FMT) is the process of transplanting stool from a healthy donor into the gut of a patient for therapeutic purposes. Current guidelines recommend FMT for the prevention of multiply recurrent Clostridioides difficile infection (CDI) after two recurrences, with cure rates approaching 90%. Emerging evidence also supports the use of FMT in the management of severe and fulminant CDI, resulting in decreased mortality and colectomy rates compared with standard of care approach. FMT shows promise as salvage therapy for critically-ill, refractory CDI patients who are poor surgical candidates. FMT should be considered early in the clinical course of severe CDI, preferably within 48 hours of failing to respond to antibiotic therapy and volume resuscitation. Besides CDI, ulcerative colitis was more recently identified as a potential treatment target for FMT. Several live biotherapeutics for microbiome restoration are on the horizon.

Keywords

Clostridioides difficile - colitis - toxic megacolon - fecal microbiota transplantation - colonoscopy - colectomy

Publikationsverlauf

Artikel online veröffentlicht:
25. Januar 2023

• References

• 1 Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation?. Am J Gastroenterol 2012; 107 (11) 1755 , author reply 1755–1756
• 2 Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958; 44 (05) 854-859
• 3 Lawson PA, Citron DM, Tyrrell KL, Finegold SM. Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole 1935) Prévot 1938. Anaerobe 2016; 40: 95-99
• 4 Khoruts A, Sadowsky MJ. Understanding the mechanisms of faecal microbiota transplantation. Nat Rev Gastroenterol Hepatol 2016; 13 (09) 508-516
• 5 Thorpe CM, Kane AV, Chang J, Tai A, Vickers RJ, Snydman DR. Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin. PLoS One 2018; 13 (08) e0199810
• 6 Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. Clostridium difficile infection. Nat Rev Dis Primers 2016; 2: 16020
• 7 McFarland LV, Surawicz CM, Greenberg RN. et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271 (24) 1913-1918
• 8 Chang JY, Antonopoulos DA, Kalra A. et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008; 197 (03) 435-438
• 9 Wilson KH, Perini F. Role of competition for nutrients in suppression of Clostridium difficile by the colonic microflora. Infect Immun 1988; 56 (10) 2610-2614
• 10 Weingarden AR, Dosa PI, DeWinter E. et al. Changes in colonic bile acid composition following fecal microbiota transplantation are sufficient to control Clostridium difficile germination and growth. PLoS One 2016; 11 (01) e0147210
• 11 Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell 2014; 157 (01) 121-141
• 12 Kelly CR, Fischer M, Allegretti JR. et al. ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. Am J Gastroenterol 2021; 116 (06) 1124-1147
• 13 Johnson S, Lavergne V, Skinner AM. et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis 2021; 73 (05) 755-757
• 14 van Prehn J, Reigadas E, Vogelzang EH. et al; Guideline Committee of the European Study Group on Clostridioides difficile. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect 2021; 27 (Suppl. 02) S1-S21
• 15 Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013; 108 (Suppl. 04) 500-508
• 16 Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53 (10) 994-1002
• 17 Cammarota G, Masucci L, Ianiro G. et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2015; 41 (09) 835-843
• 18 Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009; 58 (06) 403-410
• 19 Cornely OA, Crook DW, Esposito R. et al; OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12 (04) 281-289
• 20 Bhangu A, Nepogodiev D, Gupta A, Torrance A, Singh P. West Midlands Research Collaborative. Systematic review and meta-analysis of outcomes following emergency surgery for Clostridium difficile colitis. Br J Surg 2012; 99 (11) 1501-1513
• 21 Steele SR, McCormick J, Melton GB. et al. Practice parameters for the management of Clostridium difficile infection. Dis Colon Rectum 2015; 58 (01) 10-24
• 22 Kulaylat AS, Kassam Z, Hollenbeak CS, Stewart Sr DB. A surgical clostridium-associated risk of death score predicts mortality after colectomy for Clostridium difficile . Dis Colon Rectum 2017; 60 (12) 1285-1290
• 23 Juo YY, Sanaiha Y, Jabaji Z, Benharash P. Trends in diverting loop ileostomy vs total abdominal colectomy as surgical management for Clostridium difficile colitis. JAMA Surg 2019; 154 (10) 899-906
• 24 Felsenreich DM, Gachabayov M, Rojas A, Latifi R, Bergamaschi R. Meta-analysis of postoperative mortality and morbidity after total abdominal colectomy versus loop ileostomy with colonic lavage for fulminant Clostridium difficile colitis. Dis Colon Rectum 2020; 63 (09) 1317-1326
• 25 Fashandi AZ, Wang PT, Hedrick TL, Friel CM, Hays RA, Hallowell PT. Recurrent Clostridium difficile infection after diverting loop ileostomy and colonic lavage: an unreported complication of the novel surgical therapy. Am Surg 2017; 83 (08) e335-e338
• 26 Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg 2011; 254 (03) 423-427 , discussion 427–429
• 27 Zainah H, Hassan M, Shiekh-Sroujieh L, Hassan S, Alangaden G, Ramesh M. Intestinal microbiota transplantation, a simple and effective treatment for severe and refractory Clostridium difficile infection. Dig Dis Sci 2015; 60 (01) 181-185
• 28 Agrawal M, Aroniadis OC, Brandt LJ. et al. The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated Clostridium difficile infection in 146 elderly individuals. J Clin Gastroenterol 2016; 50 (05) 403-407
• 29 Weingarden AR, Hamilton MJ, Sadowsky MJ, Khoruts A. Resolution of severe Clostridium difficile infection following sequential fecal microbiota transplantation. J Clin Gastroenterol 2013; 47 (08) 735-737
• 30 Fischer M, Sipe BW, Rogers NA. et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther 2015; 42 (04) 470-476
• 31 Fischer M, Sipe B, Cheng YW. et al. Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: a promising treatment approach. Gut Microbes 2017; 8 (03) 289-302
• 32 Ianiro G, Masucci L, Quaranta G. et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions. Aliment Pharmacol Ther 2018; 48 (02) 152-159
• 33 Seder CW, Villalba Jr MR, Robbins J. et al. Early colectomy may be associated with improved survival in fulminant Clostridium difficile colitis: an 8-year experience. Am J Surg 2009; 197 (03) 302-307
• 34 Cammarota G, Ianiro G, Magalini S, Gasbarrini A, Gui D. Decrease in surgery for Clostridium difficile infection after starting a program to transplant fecal microbiota. Ann Intern Med 2015; 163 (06) 487-488
• 35 Cheng YW, Phelps E, Nemes S. et al. Fecal microbiota transplant decreases mortality in patients with refractory severe or fulminant Clostridioides difficile infection. Clin Gastroenterol Hepatol 2020; 18 (10) 2234-2243.e1
• 36 Cheng Y-W, Phelps E, Rogers N. et al. Fecal Microbiota Transplant Decreases Mortality in Patients with Severe and Severe-Complicated Clostridium difficile Infection, Including Cases Not Eligible for Colectomy. Paper presented at: World Congress of Gastroenterology at ACG; October 13–18, 2017; Orlando, FL
• 37 Hocquart M, Lagier J-C, Cassir N. et al. Early fecal microbiota transplantation improves survival in severe Clostridium difficile infections. Clin Infect Dis 2018; 66 (05) 645-650
• 38 Tixier EN, Verheyen E, Ungaro RC, Grinspan AM. Faecal microbiota transplant decreases mortality in severe and fulminant Clostridioides difficile infection in critically ill patients. Aliment Pharmacol Ther 2019; 50 (10) 1094-1099
• 39 Ianiro G, Murri R, Sciumè GD. et al. Incidence of bloodstream infections, length of hospital stay, and survival in patients with recurrent Clostridioides difficile infection treated with fecal microbiota transplantation or antibiotics: a prospective cohort study. Ann Intern Med 2019; 171 (10) 695-702
• 40 Allegretti JR, Kassam Z, Osman M, Budree S, Fischer M, Kelly CR. The 5D framework: a clinical primer for fecal microbiota transplantation to treat Clostridium difficile infection. Gastrointest Endosc 2018; 87 (01) 18-29
• 41 Wortelboer K, Nieuwdorp M, Herrema H. Fecal microbiota transplantation beyond Clostridioides difficile infections. EBioMedicine 2019; 44: 716-729
• 42 Allegretti JR, Mullish BH, Kelly C, Fischer M. The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications. Lancet 2019; 394 (10196): 420-431
• 43 Rossen NG, Fuentes S, van der Spek MJ. et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 2015; 149 (01) 110-118.e4
• 44 Moayyedi P, Surette MG, Kim PT. et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 2015; 149 (01) 102-109.e6
• 45 Paramsothy S, Kamm MA, Kaakoush NO. et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 2017; 389 (10075): 1218-1228
• 46 Costello SP, Hughes PA, Waters O. et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA 2019; 321 (02) 156-164
• 47 Haifer C, Paramsothy S, Kaakoush NO. et al. Lyophilised Oral Faecal Microbiota Transplantation for Ulcerative Colitis (LOTUS): a randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol 2022; 7 (02) 141-151
• 48 Imdad A, Nicholson MR, Tanner-Smith EE. et al. Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database Syst Rev 2018; 11 (11) CD012774
• 49 Ohkusa T, Nomura T, Terai T. et al. Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol 2005; 40 (11) 1334-1342
• 50 Bafeta A, Yavchitz A, Riveros C, Batista R, Ravaud P. Methods and reporting studies assessing fecal microbiota transplantation: a systematic review. Ann Intern Med 2017; 167 (01) 34-39
• 51 Voth E, Khanna S. Fecal microbiota transplantation for treatment of patients with recurrent Clostridioides difficile infection. Expert Rev Anti Infect Ther 2020; 18 (07) 669-676
• 52 Orenstein R, Dubberke E, Hardi R. et al; PUNCH CD Investigators. Safety and durability of RBX2660 (microbiota suspension) for recurrent Clostridium difficile infection: results of the PUNCH CD study. Clin Infect Dis 2016; 62 (05) 596-602
• 53 Orenstein R, Dubberke ER, Khanna S. et al. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial. BMC Infect Dis 2022; 22 (01) 245
• 54 Efficacy, safety, and tolerability study of oral full-spectrum MicrobiotaTM (CP101) in subjects with recurrent C. Diff (PRISM3). Accessed May 9, 2022 at: https://clinicaltrials.gov/ct2/show/NCT03110133;RBX7455
• 55 Feuerstadt P, Louie TJ, Lashner B. et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N Engl J Med 2022; 386 (03) 220-229
• 56 VE303 (Phase 2 study of VE303 for prevention of recurrent Clostridium Difficile infection (CONSORTIUM). Accessed May 9, 2022 at: https://www.clinicaltrials.gov/ct2/show/NCT03788434